Faculty and Disclosure Statements
Activity Director: James Tsai, MD, MBA
James C. Tsai, MD, MBA, is the president of New York Eye and Ear Infirmary of Mount Sinai and chair of ophthalmology for the Mount Sinai Health System. Dr. Tsai states that in the last 12 months, he has been a consultant for Aerie Pharmaceuticals and Inotek Pharmaceuticals.
CME Reviewer: Matthew J. Gray, MD
Matthew J. Gray, MD, is an assistant professor at the department of ophthalmology
at the University of Florida College of Medicine. Dr. Gray states that in the past 12 months, he has not had a financial relationship with any commercial organization that produces, markets, resells, or distributes healthcare goods or services consumed by or used on patients relevant to this manuscript.
Video #1: Basic Science and Clinical Introduction
Joseph Caprioli, MD, is the David May II Professor of Ophthalmology, chief of the Glaucoma Division, and director of the Glaucoma Basic Science and Clinical Laboratories, Jules Stein Eye Institute, at the University of California, Los Angeles. Dr. Caprioli states that in the past 12 months, he has not had a financial relationship with any commercial organization that produces, markets, resells, or distributes healthcare goods or services consumed by or used on patients relevant to this manuscript.
Paul L. Kaufman, MD, is the Ernst H. Bárány Professor of Ocular Pharmacology and Peter A. Duehr Professor and Department Chair Emeritus at the University of Wisconsin School of Medicine and Public Health in Madison, WI. Dr. Kaufman states that in the last 12 months, he has been a consultant for Applied Genetic Technologies Corporation, Alcon, Allergan, Bausch + Lomb, Amakem Therapeutics, Refocus Group, Sucampo Pharmaceuticals, and Valeant Pharmaceuticals. Dr. Kaufman also states that he has received grants from Lens AR, Inc./Frey Research LLC, ZLens LLC, WARF, Vista Ocular LLC, and ReGen Eye. Dr. Kaufman also states that he has received royalties from WARF.
Video #2: New Drug Classes
Eydie Miller-Ellis, MD, is a professor of clinical ophthalmology and director of the glaucoma service at Scheie Eye Institute at the University of Pennsylvania. Dr. Miller-Ellis states that in the last 12 months, she has received grant/research support from Aerie Pharmaceuticals and Allergan, and has also served as a consultant for Alcon and Ono.
Robert Noecker, MD, MBA, is an assistant clinical professor of ophthalmology at the Yale University School of Medicine and practices at Ophthalmic Consultants of Connecticut. Dr. Noecker states that in the last 12 months, he has received grant/research support from Glaukos, InnFocus, and Aquesys, Inc., and been a consultant for Alcon, Allergan, Ocular Therapeutix, Inc., IRIDEX, Inotek Pharmaceuticals, Santen Pharmaceutical, SOLX, Aerie Pharmaceuticals, Beaver-Visitec International, and Sun Ophthalmics. Dr. Noecker also states that he has been on the speakers bureau for Alcon, Allergan, IRIDEX, Glaukos, and Beaver-Visitec International, and is a stock shareholder for Ocular Therapeutix.
Video #3: Improved Drug Use and Delivery
Angelo Tanna, MD, is Vice Chairman, associate professor of ophthalmology, and director of the Glaucoma Service at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. Dr. Tanna states that in the last 12 months, he has been a consultant for Aeon Astron, Apotex, Bausch + Lomb, Alcon, Sandoz, and Watson Pharmaceuticals.
Rohit Varma, MD, MPH, is Interim Dean, at the Keck School of Medicine at the University of Southern California, director of the USC Eye Institute, and professor and chair of the department of ophthalmology at the Keck School of Medicine at the University of Southern California. Dr. Varma states that in the last 12 months, he has been a consultant for Aerie Pharmaceuticals, Allergan, Bausch + Lomb, Genentech, and Isarna Therapeutics.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and professional development. The information presented in this activity is not meant to serve as a guideline for patient care. Procedures, medications, and other courses of diagnosis and treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Commercial Supporters: This activity is supported by an unrestricted educational grant from Bausch + Lomb, Inc.